[go: up one dir, main page]

PE20160991A1 - Bioconjugados de polipeptidos de apelina sintetica - Google Patents

Bioconjugados de polipeptidos de apelina sintetica

Info

Publication number
PE20160991A1
PE20160991A1 PE2016000097A PE2016000097A PE20160991A1 PE 20160991 A1 PE20160991 A1 PE 20160991A1 PE 2016000097 A PE2016000097 A PE 2016000097A PE 2016000097 A PE2016000097 A PE 2016000097A PE 20160991 A1 PE20160991 A1 PE 20160991A1
Authority
PE
Peru
Prior art keywords
bioconjugates
nal
polypeptide
absent
peptide
Prior art date
Application number
PE2016000097A
Other languages
English (en)
Inventor
Shari L Caplan
Andrei Golosov
Philipp Grosche
Carla Guimaraes
Aaron Kanter
Changgang Lou
Hongjuan Zhao
Eric C Peters
Aimee Richardson Usera
Kayo Yasoshima
Jun Yuan
Frederic Zecri
David Thomas Parker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20160991A1 publication Critical patent/PE20160991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)

Abstract

Se refiere a bioconjugados que comprenden: a) un peptido o polipeptido de formula I’, donde X1 esta ausente, o se selecciona entre R, Q, A, K, entre otros; X2 es R, A, K, H, F, E, entre otros; X3 es P, A, K, D, entre otros; X4 es R, A, F, E, entre otros; X5 es L, A, K, D, F, entre otros; X6 y X12 son independientemente C, K, D, Orn, Dab, E, entre otros, donde X6 y X12 estan unidos a traves de un enlace covalente –S–, –SS–, –NHC(O)– o –C(O)NH–; X7 es H, A, Aib, K, Nal, F, P, Dap, N, E, entre otros; X8 es K, F, A, E, entre otros; X9 es G, A, D, L, R, entre otros; X10 es P, A, 4-PhP, entre otros; X11 es M, Nle, A, F, Y, L, K, entre otros; y X13 esta ausente, o se selecciona entre F, Nal, F, I, A, K, H, E, entre otros; y b) una fraccion de extension de vida media, unida covalentemente o fusionada mediante un enlazador al peptido o polipeptido de formula I’. En un aspecto preferido, la fraccion de extension de vida media es un dominio constante de IgG o fragmento del mismo, o una albumina de suero humano. Tambien se refiere a composiciones farmaceuticas comprendiendo dichos bioconjugados, y a combinaciones de los mismos con uno o mas co-agentes terapeuticamente activos, tales como inotropos, bloqueadores de receptores beta-adrenergicos, entre otros. Dichos conjugados son utiles en el tratamiento o prevencion de insuficiencias cardiacas, aterosclerosis, hipertension, arritmia, obesidad, entre otros
PE2016000097A 2013-07-25 2014-07-21 Bioconjugados de polipeptidos de apelina sintetica PE20160991A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361858303P 2013-07-25 2013-07-25
US201462015848P 2014-06-23 2014-06-23

Publications (1)

Publication Number Publication Date
PE20160991A1 true PE20160991A1 (es) 2016-10-15

Family

ID=51265872

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000097A PE20160991A1 (es) 2013-07-25 2014-07-21 Bioconjugados de polipeptidos de apelina sintetica

Country Status (22)

Country Link
US (2) US9340582B2 (es)
EP (1) EP3024492A2 (es)
JP (1) JP2016527249A (es)
KR (1) KR20160031552A (es)
CN (1) CN105705167A (es)
AP (1) AP2016009019A0 (es)
AU (1) AU2014293387B2 (es)
BR (1) BR112016001376A2 (es)
CA (1) CA2918077A1 (es)
CL (1) CL2016000157A1 (es)
CR (1) CR20160049A (es)
CU (1) CU20160012A7 (es)
EA (1) EA201690282A1 (es)
HK (1) HK1218252A1 (es)
IL (1) IL243691A0 (es)
MX (1) MX2016001021A (es)
PE (1) PE20160991A1 (es)
PH (1) PH12016500103A1 (es)
SG (1) SG11201600208RA (es)
TW (1) TW201518323A (es)
UY (1) UY35671A (es)
WO (1) WO2015013169A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
UY35144A (es) * 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
EP3024846A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
PE20160991A1 (es) * 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
CN105916881A (zh) 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
JP6675333B2 (ja) 2014-06-23 2020-04-01 ノバルティス アーゲー 部位特異的タンパク質修飾
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2016014501A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Sortase molecules and uses thereof
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CA2972871A1 (en) * 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
TWI614030B (zh) * 2015-05-20 2018-02-11 免疫功坊股份有限公司 具有標的部分及效應部分的分子構建體
US11484577B2 (en) 2016-02-15 2022-11-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction
JP2019508419A (ja) * 2016-02-16 2019-03-28 ザ ユニバーシティー オブ クイーンズランド 新規アルファコノトキシンペプチド
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US11753438B2 (en) 2016-05-11 2023-09-12 Cytiva Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
CN110072531A (zh) 2016-10-19 2019-07-30 阿维夫公司 用于治疗心血管相关疾病的爱帕琳的新型聚乙二醇化的脂质体制剂
JP7001285B2 (ja) * 2017-03-29 2022-01-19 国立大学法人 宮崎大学 長時間作用型アドレノメデュリン誘導体
US10639382B2 (en) 2017-04-13 2020-05-05 National Guard Health Affairs Method for treating leukemia
EP3649146B1 (en) 2017-07-03 2024-06-26 The Governors of the University of Alberta Apelin peptides and uses thereof
CN113194983B (zh) * 2018-09-06 2025-11-18 奇达拉治疗公司 用于治疗病毒感染的组合物及方法
KR102509217B1 (ko) * 2020-08-28 2023-03-14 기초과학연구원 시스테인 선택적 결합 퀴놀리논 유도체 화합물, 이의 펩티드 결합체 및 이를 포함하는 항체-약물 접합체
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
GB202308304D0 (en) 2023-06-02 2023-07-19 Univ Ulster A fusion peptide for activation of the apj and/or glp-1 receptors

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
DE3347565A1 (de) 1983-12-30 1985-07-11 Thomae Gmbh Dr K Neue phenylessigsaeurederivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
AU654331B2 (en) 1991-03-30 1994-11-03 Kissei Pharmaceutical Co. Ltd. Succinic acid compounds
US5155100A (en) 1991-05-01 1992-10-13 Ciba-Geigy Corporation Phosphono/biaryl substituted dipeptide derivatives
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE10075006I2 (de) 1991-06-21 2004-01-08 Boehringer Ingelheim Pharma Verwendung von (S)(+)-2-Äthoxy-4-[N-[1-(2-Piperidino-Phenyl)-3-Methyl-1-Butyl[Aminocarbonylmethyl]-Benzoesäure zur Herstellung eines Langzeitantidiabetikums.
DK0526171T3 (da) 1991-07-30 1997-08-25 Ajinomoto Kk Krystaller af N-(trans-4-isopropylcyclohexylcarbonyl)-Dphenylalanin og fremgangsmåder til fremstilling deraf
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
EP0630405B1 (en) 1992-11-17 1998-04-08 Icos Corporation Novel V28 seven transmembrane receptor
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
TW313568B (es) 1994-12-20 1997-08-21 Hoffmann La Roche
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
EP1040189B1 (en) 1997-12-24 2008-01-09 Takeda Pharmaceutical Company Limited Polypeptides, their production and use
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU5759399A (en) 1998-09-25 2000-04-17 Takeda Chemical Industries Ltd. Peptide derivative
EP1120425B1 (en) 1998-10-05 2009-08-26 Takeda Pharmaceutical Company Limited Process for eliminating n-terminal methionine
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US7045532B2 (en) 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
US6677341B2 (en) 1999-09-23 2004-01-13 Pharmacia Corporation (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
DE60119714T2 (de) 2000-03-23 2006-09-07 Takeda Chemical Industries, Ltd. Peptidderivat
NZ521855A (en) 2000-04-12 2004-10-29 Novartis Ag Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a dirruretic to treat various conditions
WO2001090123A2 (en) 2000-05-23 2001-11-29 Genaissance Pharmaceuticals, Inc. Haplotypes of the agtrl1 gene
EP2128246B1 (en) 2001-04-19 2014-03-12 The Scripps Research Institute Methods and compositions for the production of orthogonal tRNA-Aminoacyl-tRNA synthetase pairs
IL159857A0 (en) 2001-07-16 2004-06-20 Hk Pharmaceuticals Inc Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
WO2003063892A1 (en) 2002-01-29 2003-08-07 Takeda Chemical Industries, Ltd. Use of apelin
WO2003104200A1 (en) 2002-06-07 2003-12-18 Glaxo Group Limited N-mercaptoacyl phenyalanine derivatives, process for their preparation, and pharmaceutical compositions containing them
ATE335744T1 (de) 2002-08-07 2006-09-15 Novartis Pharma Gmbh Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
AU2003292039A1 (en) 2002-11-18 2004-06-15 Novartis Ag Imidazo(1, 5a)pyridine derivatives and methods for treating aldosterone mediated diseases
US7736646B2 (en) 2003-03-12 2010-06-15 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis with apelin compositions
US7947280B2 (en) * 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
EP1656560A2 (en) 2003-05-22 2006-05-17 Agilent Technologies, Inc. Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
EP1520861A1 (en) 2003-09-11 2005-04-06 Aventis Pharma Deutschland GmbH Test system for the identification of APJ receptor ligands
JP2007531707A (ja) 2003-10-15 2007-11-08 ピーディーエル バイオファーマ， インコーポレイテッド ＩＧの重鎖定常領域の位置２５０、３１４および／または４２８の変異誘発によるＦｃ融合タンパク質血清半減期の改変
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20080076794A1 (en) 2004-05-28 2008-03-27 Peter Herold Heterocyclic Compounds And Their Use As Aldosterone Synthase Inhibitors
BRPI0511621A (pt) 2004-05-28 2008-01-02 Speedel Experimenta Ag compostos orgánicos
EP1749006A2 (en) 2004-05-28 2007-02-07 Speedel Experimenta AG Heterocyclic compounds and their use as aldosterone synthase inhibitors
AU2005265164A1 (en) 2004-06-17 2006-01-26 Musc Foundation For Research Development Non-natural amino acids
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
WO2006023893A2 (en) 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
JP2008013436A (ja) 2004-10-14 2008-01-24 Kanazawa Univ 血管形成促進剤
WO2006047558A2 (en) 2004-10-26 2006-05-04 The General Hospital Corporation Methods for detecting a trial fibrillation and related conditions
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20060159676A1 (en) 2005-01-14 2006-07-20 Krieg Paul A Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
EP1929073A4 (en) * 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
EP1876448A1 (en) 2005-09-30 2008-01-09 DIGILAB BioVisioN GmbH Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones.
US7736346B2 (en) 2005-10-18 2010-06-15 Biocardia, Inc. Bio-interventional therapeutic treatments for cardiovascular diseases
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
US20080031871A1 (en) 2006-02-21 2008-02-07 Allen Margaret L Memory and learning impairments associated with disruption of Ephrin receptor A6 (EphA6) gene
CN101415803B (zh) 2006-04-04 2012-10-24 大阳日酸株式会社 甲烷分离方法、甲烷分离装置以及甲烷利用系统
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
JPWO2007123233A1 (ja) 2006-04-25 2009-09-10 国立大学法人九州大学 動脈硬化性疾患関連遺伝子、およびその利用
MX2008014284A (es) 2006-05-10 2008-11-18 Novartis Ag Derivados biciclicos como inhibidores de cetp.
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
EP2049517B1 (en) 2006-07-20 2013-11-27 Novartis AG Amino-piperidine derivatives as cetp inhibitors
CN101506216A (zh) 2006-08-25 2009-08-12 诺瓦提斯公司 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物
EP2094680A2 (en) 2006-12-18 2009-09-02 Novartis AG Imidazoles as aldosterone synthase inhibitors
KR20090094374A (ko) 2006-12-18 2009-09-04 노파르티스 아게 1-치환된 이미다졸 유도체 및 알도스테론 신타제 억제제로서의 그의 용도
JP2010513558A (ja) 2006-12-18 2010-04-30 ノバルティス アーゲー ４−イミダゾリル−１，２，３，４−テトラヒドロキノリン誘導体、およびアルドステロン／１１−ベータ−ヒドロキシラーゼ阻害剤としてのその使用
MX2009008264A (es) 2007-03-29 2009-08-12 Novartis Ag Compuestos espiro heterociclicos.
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
WO2009035543A1 (en) 2007-09-07 2009-03-19 Theravance, Inc. Dual-acting antihypertensive agents
WO2009033819A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
EP2187935A2 (en) 2007-09-11 2010-05-26 Mondobiotech Laboratories AG Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys-oh as a therapeutic agent
HRP20120476T1 (hr) 2007-11-05 2012-06-30 Novartis Ag Derivati 4-benzilamino-1-karboksiacil-piperidina kao cetp inhibitori korisni za liječenje bolesti kao što su hiperlipidemija ili arterioskleroza
EA017939B1 (ru) 2007-12-03 2013-04-30 Новартис Аг Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
WO2009075566A1 (en) 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
US20110123534A1 (en) 2007-12-12 2011-05-26 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
EP2297113A1 (en) 2008-04-29 2011-03-23 Theravance, Inc. Dual-acting antihypertensive agents
WO2009155556A2 (en) * 2008-06-20 2009-12-23 The Board Of Regents Of The University Of Texas System Crkl targeting peptides
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
KR20130086386A (ko) 2008-10-24 2013-08-01 아이알엠 엘엘씨 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
CN102203117A (zh) 2008-11-04 2011-09-28 安科治疗公司 Apj受体化合物
US20110294738A1 (en) * 2008-11-04 2011-12-01 Yong Ren Pthr1 receptor compounds
WO2010115874A1 (en) 2009-04-07 2010-10-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
JP5420761B2 (ja) 2009-05-28 2014-02-19 ノバルティス アーゲー ネプリリシン阻害剤としての置換アミノプロピオン酸誘導体
EP2496243A2 (en) 2009-11-04 2012-09-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
WO2011133948A2 (en) 2010-04-22 2011-10-27 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2457216C1 (ru) 2010-12-21 2012-07-27 Федеральное государственное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития Российской Федерации (ФГУ "РКНПК" Минздравсоцразвития России) Додекапептиды, обладающие кардиопротекторными свойствами
DK2683360T3 (en) 2011-03-11 2016-05-30 Genzyme Corp PEGYLED APELIN AND APPLICATIONS THEREOF
CU23950B1 (es) * 2011-03-21 2013-10-29 Ct De Ingeniería Genética Y Biotecnología Péptidos cíclicos con actividad antineoplásica y antiangiogénica
DK2717898T3 (en) * 2011-06-10 2019-03-25 Bioverativ Therapeutics Inc COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
KR20140039257A (ko) * 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
AU2013208109A1 (en) 2012-01-09 2014-08-14 Anchor Therapeutics, Inc. APJ receptor compounds
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
JP6408480B2 (ja) * 2012-11-30 2018-10-17 ノバルティス アーゲー ジスルフィドを含むタンパク質から複合体を調製する方法
JP6426107B2 (ja) 2012-12-20 2018-11-21 アムジエン・インコーポレーテツド Ａｐｊ受容体アゴニストおよびその使用
AU2014236451B2 (en) 2013-03-14 2018-08-09 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
PE20160991A1 (es) * 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
EP3024846A1 (en) 2013-07-25 2016-06-01 Novartis AG Cyclic apelin derivatives for the treatment of heart failure
TW201536814A (zh) 2013-07-25 2015-10-01 Novartis Ag 用於治療心臟衰竭之合成環狀多肽
US9683018B2 (en) 2013-07-25 2017-06-20 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure

Also Published As

Publication number Publication date
KR20160031552A (ko) 2016-03-22
AP2016009019A0 (en) 2016-02-29
SG11201600208RA (en) 2016-02-26
MX2016001021A (es) 2016-08-03
WO2015013169A3 (en) 2015-03-19
UY35671A (es) 2015-02-27
PH12016500103A1 (en) 2016-04-18
TW201518323A (zh) 2015-05-16
WO2015013169A2 (en) 2015-01-29
AU2014293387B2 (en) 2017-04-20
CL2016000157A1 (es) 2016-07-08
AU2014293387A1 (en) 2016-02-11
IL243691A0 (en) 2016-04-21
CU20160012A7 (es) 2016-08-31
CR20160049A (es) 2016-06-17
US20160166634A1 (en) 2016-06-16
CA2918077A1 (en) 2015-01-29
WO2015013169A9 (en) 2016-10-20
HK1218252A1 (zh) 2017-02-10
US9340582B2 (en) 2016-05-17
EA201690282A1 (ru) 2016-09-30
JP2016527249A (ja) 2016-09-08
CN105705167A (zh) 2016-06-22
EP3024492A2 (en) 2016-06-01
BR112016001376A2 (pt) 2017-10-24
US20150030594A1 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
PE20160991A1 (es) Bioconjugados de polipeptidos de apelina sintetica
MX2019015742A (es) Receptores de celulas t novedosos, e inmunoterapia usando los mismos.
CO2020014180A2 (es) Derivados de gip y usos de estos
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2020006474A (es) Ligandos de peptidos biciclicos especificos para el receptor eph de tirosina quinasa a2 (epha2).
PE20130199A1 (es) Proteina de fusion robo1-fc y su utilizacion en el tratamiento de tumores
EA201491441A1 (ru) Композиции конъюгата xten и способы их получения
PE20190436A1 (es) Moleculas de union a antigeno que comprenden un trimero de ligando de la familia de tnf y un resto de union a pd1
ME03709B (me) Fuzijski proteini
PE20091931A1 (es) Proteinas de dominio de armazon basadas en fibronectina multivalentes
GT200900304A (es) "antagonistas ciclicos de peptido cxcr4"
CR20160048A (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca
BR122016022033B8 (pt) conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica
PE20142194A1 (es) Mimeticos de apelina sinteticos para el tratamiento de insuficiencia cardiaca
PE20121643A1 (es) Polipeptidos del factor ix modificados y usos de los mismos
ES2722799T3 (es) Vacunas contra el cáncer de cerebro basadas en el péptido alfa 2 del receptor de interleuquina-13
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
MX388822B (es) Composiciones que comprenden peptido wkdeagkplvk.
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
US11654178B2 (en) Cyclic prosaposin peptides and uses thereof
CL2018000131A1 (es) Inmunoconjugados de il22
JP2017502003A5 (es)
RU2017132689A (ru) СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE
DOP2022000097A (es) Agonistas del receptor npy2

Legal Events

Date Code Title Description
FD Application declared void or lapsed